In this online, self-learning activity:
Systemic sclerosis (SSc) is a rare connective tissue disease that affects 276 people per million in the U.S., of whom around 70% will experience interstitial lung disease (ILD). The disease is characterized by a progressive course of scarring to the blood vessels underlying the skin, connective tissue, joints, and organs. The pathology of SSc remains to be fully elucidated, but different immunologic and genetic pathways have been explored as potential precipitating factors for SSc. Based on what is known, SSc-ILD may be summarized into three steps: 1) continuous injury to endothelial cells, 2) activation of innate and adaptive immunity, 3) recruitment and activation of fibroblasts.
The following HCPs: pulmonologists, rheumatologists, primary care physicians, pathologists, dermatologists; physician assistants, nurse practitioners, nurses, and pharmacists specializing in pulmonology; and any other HCPs who have an interest in or otherwise clinically encounter patients with Ssc-ILD.
This program is supported by an educational grant from Boehringer Ingelheim.
Release Date: August 20, 2018 -- Expiration Date: August 20, 2020
Faculty: Terese Hammond, MD
Cursory refresher and review on SSc-ILD epidemiology and diagnosis:
Treatment of SSc-ILD:
By the end of the session the participant will be able to:
ACCME Activity #201226485
THIS COURSE IS EXPIRED. NO CREDIT WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Dr. Terese C. Hammond, MD, Clinical Professor, University of Southern California, Los Angeles, CA has no relevant conflicts of interest to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Boehringer Ingelheim.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Alpha-1 antitrypsin deficiency (AATD): improving treatment and reducing barriers to care